- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03725878
Effectiveness of Comprehensive Tertiary Interventions on Incidence and Clinical Outcomes of Birth Defects
Effectiveness of Comprehensive Tertiary Interventions on Incidence and Clinical Outcomes of Birth Defects : a Cluster Randomisation Intervention Trial
Study Overview
Status
Conditions
Detailed Description
According to World health Organization (WHO), approximately 3.2 million children are born with birth defect(s) worldwide and the incidence of birth defects in China is 5.6%. Birth defects are the main cause of fetal death, infant mortality and morbidity, and long-term disability. Congenital heart defects, oral clefts, hydrocephalus, neural tube defects and mental retardation are most common birth defects in China. Though the etiology of birth defects is still unknow, many studies indicated that maternal key nutrition factors, especially maternal folic acid status, during periconception played an important role in organogenesis, reducing the incidence of neural tube defects, congenital heart diseases and some other birth defects.
Our project is a single-blind, cluster randomized controlled trial that aim at evaluating whether hospital-based tertiary intervention approaches reduce the incidence of birth defects (compound primary outcomes, including neural tube defects, congenital heart defects, cleft lips and palates, hydrocephalus, alimentary tract malformations or urological deformities) that identified at middle of gestation via ultrasound or clinical observation at birth. Every couple attending premarital check or preconception physical examination from Minhang and Songjiang district in Shanghai will be recruited. Recruited couples are to draw blood samples and invite to complete questionnaires that collecting informations on diet supplementation. Comprehensive interventions before conception are based on serum folate, red blood cell folate, homocysteine, vitamin B12 and fasting glycemic and lipids profiles. Single nucleotide polymorphisms related to folate and homocysteine matalism pathway will be genotyped in participants with sufficient intake of folic acid but unknown deficiency of the nutrients. Venous blood of pregnant women and questionnaires about the supplementation of key nutrients at the first antenatal visit are also obtained. NT examination, Down's screening, and ultrasound examination results are collected during the second trimester (15-24 gestational week), then routine prenatal genetic counseling, assessment, and diagnosis are provided according to the local policy to those pregnant women with positive screen results indicating high risk of fatal birth defects. Newborns with above mentioned birth defects are provided green channel to clinical specialty team for further diagnosis, surgical correction and rehabilitation guidance. Clinical follow up will be conducted till 6-month old for the prognosis of treatment. The current project will provide evidence on the necessity and effectiveness of preconception intervention focusing on sufficient folate nutrition levels in prevention of birth defects.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wei L Yan, Ph.D
- Phone Number: 86 21 64931215 86 21 64931215
- Email: yanwl@fudan.edu.cn
Study Contact Backup
- Name: Ying G Huang, MD, Ph.D
- Phone Number: 86-21-64931913 86-21-64931928
- Email: gyhuang@shmu.edu.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201102
- Children Hospital of Fudan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females and their husbands attend pre-pregnancy physical examinations from Minhang distrit and Songjiang distrit in Shanghai.
- Couples who have planned to be pregnant within a year
- Women are between 18 and 45 years old
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional
Standard tertiary interventions of birth defects; Additional preconception health care; Additional health care procedures during and after pregnancy.
|
Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations).
But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al.
Regular antenatal cares are required, such as deformity screening by ultrasound.
Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
Other Names:
Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares.
Therefore, we evaluate subject's folate level by serum and red blood cell folate examination.
By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects.
Red blood cell folate concentration >400 ng/ml before pregnancy is recommended.
Other Names:
Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions.
A 6-months follow up will be conducted to follow children's birth outcomes.
It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
Other Names:
|
Active Comparator: Control
Standard tertiary interventions of birth defects; Additional health care procedures during and after pregnancy.
|
Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations).
But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al.
Regular antenatal cares are required, such as deformity screening by ultrasound.
Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
Other Names:
Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions.
A 6-months follow up will be conducted to follow children's birth outcomes.
It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of total fetal birth defects found during the second trimester, still birth, and neontal birth defects identified after delivery
Time Frame: From the confirmation of pregnant to 28 days after birth
|
This is a composite outcome: the total number of fetus defects detected by Down's syndrome screenings, NT examinations and Ultrasound image examinations during the second trimester, stillbirth, and the number of birth defects after delivery diagnosed by clinical team. (Defects are classified in consistent with our birth defect monitoring policy, which have 24 types of defects: Anencephalus; Spina bifida; Encephalocele; Congenital Hydrocephalus; Cleft Palate; Cleft Lip; Cleft Lip with Cleft Palate; Microtia (including Anotia); Deformity of external ear(s) (except Microtia and Anotia); Esophageal atresia or stenosis; Anorectal atresia (including Congenital Anorectal Malformations); Hypospadia; Ectopocystis; Pes Equinovarus; Polydactylism; Syndactylia; Limb shortening; Congenital Diaphragmatic Hernia; Pcromphalus; Celoschisis; Conjoined Twins; Trisomy 21 syndrome; Congenital heart disease; Others. ) |
From the confirmation of pregnant to 28 days after birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence rate of total abortion because of the affected congenital defects
Time Frame: From the confirmation of pregnant to the 28th gestational week
|
Reasons of abortion are recorded
|
From the confirmation of pregnant to the 28th gestational week
|
Incidence of death or severe organ dysfunctions
Time Frame: From birth to 6 months after delivery ( can be expanding to the end of the 7th month)
|
Severe organ dysfunctions were defined based on specialty clinical examinaitons
|
From birth to 6 months after delivery ( can be expanding to the end of the 7th month)
|
Extra medical cost that relates to affecting any birth defects during pregnancy and after birth
Time Frame: From confirmation of pregnancy to one year old after birth
|
Additional medical cost that exceeds normal pregnancies and children within one year old
|
From confirmation of pregnancy to one year old after birth
|
incidence of congenital heart defect
Time Frame: from conception to one year old
|
congenital heart defects diagnosed during pregnancy (ultrasound) and after birth( Echocardiography).
(Definition see Zhao et al.
Lancet 2014)
|
from conception to one year old
|
Total pregnancy loss
Time Frame: from conception to 28 gestational weeks
|
artificial abortions without any medical reasons were exluded
|
from conception to 28 gestational weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Ying G Huang, MD, Ph.D, Children's Hospital Of Fudan University
Publications and helpful links
General Publications
- Liu S, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R, Kramer MS; Canadian Perinatal Surveillance System (Public Health Agency of Canada). Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes. Circulation. 2016 Aug 30;134(9):647-55. doi: 10.1161/CIRCULATIONAHA.116.022126.
- Czeizel AE, Dudas I, Vereczkey A, Banhidy F. Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects. Nutrients. 2013 Nov 21;5(11):4760-75. doi: 10.3390/nu5114760.
- Ebadifar A, KhorramKhorshid HR, Kamali K, Salehi Zeinabadi M, Khoshbakht T, Ameli N. Maternal Supplementary Folate Intake, Methylenetetrahydrofolate Reductase (MTHFR) C677T and A1298C Polymorphisms and the Risk of Orofacial Cleft in Iranian Children. Avicenna J Med Biotechnol. 2015 Apr-Jun;7(2):80-4.
- Li M, Zhang Y, Chen X, Wang D, Ji M, Jiang Y, Dou Y, Ma X, Sheng W, Yan W, Huang G. Effectiveness of community-based folate-oriented tertiary interventions on incidence of fetus and birth defects: a protocol for a single-blind cluster randomized controlled trial. BMC Pregnancy Childbirth. 2020 Aug 20;20(1):475. doi: 10.1186/s12884-020-03154-w.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016YFC1000500(6)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Birth Defects
-
National Human Genome Research Institute (NHGRI)CompletedCongenital Abnormalities | Birth Defects | Congenital DefectsUnited States
-
Boston Children's HospitalBoston Medical Center; National Human Genome Research Institute (NHGRI); The... and other collaboratorsRecruitingGenetic Predisposition to Disease | Genetics Disease | Genetics/Birth DefectsUnited States
-
Oslo University HospitalUniversity of BergenCompletedHeart Septal Defects, Atrial | Heart Defects,CongenitalNorway
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Septal Defects, Atrial | Heart Septal Defects, Ventricular | Endocardial Cushion Defects | Defect, Congenital Heart
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Septal Defects, Atrial | Heart Septal Defects, Ventricular | Endocardial Cushion Defects | Defect, Congenital Heart
-
SeptRx, Inc.UnknownHeart Septal Defects | Heart Defects, Congenital | Foramen Ovale, PatentGermany, France
-
National Human Genome Research Institute (NHGRI)Completed
-
Carag AGCompleted
-
Oslo University HospitalBioPhausiaCompletedHeart Defects, Congenital | Transposition of Great Vessels | Heart Septal Defects, Ventricular | Endocardial Cushion Defects
-
W.L.Gore & AssociatesCompleted
Clinical Trials on Standard tertiary interventions of birth defects
-
Institute of Biophysics and Cell Engineering of...Belarusian Medical Academy of Post-Graduate EducationNot yet recruitingSegmental Fracture - Bone LossBelarus
-
Chinese University of Hong KongRecruitingVaccination RefusalHong Kong
-
Hospices Civils de LyonRecruiting
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedAcute Myeloid LeukemiaUnited States
-
The Cleveland ClinicAmerican Association of Hip and Knee Surgeons (AAHKS)Not yet recruitingKnee Osteoarthritis | Surgery | Knee Arthropathy
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)CompletedRectal Carcinoma | Rectosigmoid CarcinomaUnited States, Guam
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Amsterdam UMC, location VUmc; Flevoziekenhuis; Slotervaart HospitalRecruiting
-
Columbia UniversityBill and Melinda Gates Foundation; United NationsCompletedChild SurvivalEthiopia, Ghana, Kenya, Malawi, Mali, Nigeria, Rwanda, Senegal, Tanzania, Uganda
-
Jonsson Comprehensive Cancer CenterSilicon Valley Community FoundationRecruitingStage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer American Joint Committee on Cancer (AJCC) v8United States